Supriya Lifescience Ltd (SUPRIYA) Q4FY26 Concall Summary - Mar-2026 Qtr
Performance Overview
- The company achieved its highest-ever quarterly revenue in Q4 FY26, reaching 277 crores, demonstrating strong execution despite industry-wide headwinds.
- A significant regulatory milestone was achieved with the Lotte facility receiving a USFDA Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) classification after a surprise inspection, reinforcing its credibility in regulated markets.
- The company successfully launched a key cardiovascular product and an ADHD product during the fiscal year, both of which began contributing to revenue in Q4 and are expected to scale up further.
- Management reaffirmed its guidance of approximately 20% annual revenue growth and an EBITDA margin of 33-35%, remaining on track to achieve the 1000 crore revenue milestone by FY27.
- Strategic focus remains on expanding in regulated markets, strengthening competitive advantage through backward integration (at 76% in FY26), and a robust pipeline of 3-4 new product launches annually.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.